Your Search Returned 29 tagged news reports
I wanted to run it past a wider audience to see if I'm grounded in reality, or out on my own island (which has happened before). Without getting into any details, we were talking about an area of potential drug research that has to do with
Inhibiting enzymes that cause changes in gene expression could decrease chemotherapy resistance in ovarian cancer patients, researchers at Georgia State University and the University of Georgia say. Dr. Susanna Greer, associate professor of biology,
Published 02 May 2014 Curis announced the issuance of US Patent No...This patent, along with related patents issued in June 2013 (US Patent no...PI3K enzymes, and in some instances mammalian target of rapamycin (mTOR), within a single molecule for
30 December 2013 0 View comments Researchers gave participants a mood-stabilising drug before testing their ability to them to determine perfect, or absolute, musical pitch. Those who took the drug were able to accurately identify the correct pitch
Chidamide is currently being evaluated in several clinical trials as a single agent or in combination with chemotherapeutic agents for the treatment of many hematological and solid cancers. According to the company, the inhibitor's anticancer effects
Genes interact in the brain, and both mutations produce the same biological effect. Pathway might represent new target for understanding and potentially treating eating disorders. Released: 10/4/2013 12:00 PM EDT Embargo expired: 10/8/2013 12:00 PM
Curis scientists and is currently in Phase I clinical testing in patients with relapsed or refractory lymphomas or multiple myeloma."
Here's a paper that combines them with another topic (epigenetics) that's been popular around here as well, even if there's some disagreement about what the word means. A group of Japanese researchers were looking at the natural products derived from
Contact Information Available for logged-in reporters only Description A healthy lung has some capacity to regenerate itself like the liver.
As per the deal, NewVac gains exclusive rights to develop and commercialize Janssen's quisinostat in Russia and other Eastern European countries. NewVac will initiate solid tumor combination therapy studies which are accompanied by translational